B
Bull
Bull · 25%CYCC
$1.30
情景价格
$6.365
-0.381 (-5.98%)收盘时
Loading chart…
- High
- 6.980
- Open
- 6.760
- VWAP
- 6.48
- Vol
- 220.50K
- Mkt Cap
- 2.49M
- Low
- 6.100
- Amount
- 1.43M
- EV/EBITDA, TTM
- 0.00
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in both the fire protection and biopharmaceutical industries. It develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. It provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel.
Analyst Ratings (1)
Buy
1 Buy
0 Hold
0 Sell
Current: 6.37
最低
—
平均
—
最高
—
Roth MKM
Strong Buy
$11
2024-05-03
Roth MKM
2024-05-03
目标价
$11
Strong Buy
Brookline Capital
Hold
—
2023-12-19
Brookline Capital
2023-12-19
目标价
—
Hold
Roth MKM
Strong Buy
$21
2023-12-19
Roth MKM
2023-12-19
目标价
$21
Strong Buy
Oppenheimer
Buy
$120
2023-05-25
Oppenheimer
2023-05-25
目标价
$120
Buy
Oppenheimer
Buy
$120
2023-03-07
Oppenheimer
2023-03-07
目标价
$120
Buy
估值指标
The current forward P/E ratio for Bio Green Med Solution Inc (CYCC) is -0.23, compared to its 5-year average forward P/E of -0.63.
Alphio AI Price Scenarios for CYCC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
8.509-12NewsfilterBio Green Med Solution, Inc. Completes Strategic Acquisition of Fitters Sdn. Bhd.
9.508-05BenzingaWhy Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
2.008-05BenzingaCyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally
- 9.008-04Newsfilter
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
2.007-21BenzingaWhy Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
CYCC FAQ — answered by Alphio AI
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in both the fire protection and biopharmaceutical industries. It develops medicines based on cell cycle, epigenetics and mitosis biology. Its Polo-like kinase 1 (PLK1) is a serine/threonine kinase with a central role in cell division and an important regulator of the DNA damage checkpoint. PLK1 overexpression correlates with poor patient prognosis in several tumors, including esophageal, gastric, leukemia, non-small cell lung cancer, ovarian, and squamous cell cancers, as well as MYC-amplified cancers. Plogosertib is a novel, small molecule, selective and potent PLK1 inhibitor. Its Fire Safety division specializes in supplying and trading various protective and fire safety equipment to both domestic and international markets. It provides fire safety products, including fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and fire safety apparel. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
1 analysts cover CYCC: 1 rate it Buy, 0 Hold and 0 Sell.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。